Treatment with E1231 in the MetS/E group results in significant reductions in NFκB activity (p < 0.05), TNF-α (p < 0.05), IL-6 (p < 0.001), TGF-β1 (p < 0.05), TIMP-1 (p < 0.05), and hydroxyproline levels (p < 0.001) compared to the MetS group. This evidence concerns the gene NFKB1 and metabolic syndrome.